A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control

A novel anticancer pro-prodrug (GMC-CAE-NO2) with diagnosis and therapy functions based on hypoxia and photo sequential control was designed. It provides a platform for constructing theranostic pro-prodrugs to release active drugs controlled by hypoxic status and UV illumination.

Saved in:
Bibliographic Details
Published inChemical communications (Cambridge, England) Vol. 52; no. 60; pp. 9434 - 9437
Main Authors Feng, Weipei, Gao, Chunyue, Liu, Wei, Ren, Huihui, Wang, Chao, Ge, Kun, Li, Shenghui, Zhou, Guoqiang, Li, Hongyan, Wang, Shuxiang, Jia, Guang, Li, Zhenhua, Zhang, Jinchao
Format Journal Article
LanguageEnglish
Published CAMBRIDGE Royal Soc Chemistry 01.01.2016
Subjects
Active control
Antineoplastic Agents - chemistry
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cell Survival - drug effects
Chemistry
Chemistry, Multidisciplinary
Construction
Diagnosis
Humans
Hypoxia
Hypoxia - diagnosis
Hypoxia - drug therapy
Illumination
MCF-7 Cells
Photochemical Processes
Physical Sciences
Platforms
Prodrugs - chemistry
Prodrugs - pharmacology
Prodrugs - therapeutic use
Science & Technology
Sequential control
Theranostic Nanomedicine
Therapy
CELL LUNG-CANCER
TRIGGERED RELEASE
DELIVERY-SYSTEM
THERAPY
SOLID TUMORS
PHASE-I TRIAL
INFRARED FLUORESCENCE PROBE
DRUG-RELEASE
PERSONALIZED MEDICINE
GEMCITABINE
Online AccessGet full text

Cover

More Information
Summary:A novel anticancer pro-prodrug (GMC-CAE-NO2) with diagnosis and therapy functions based on hypoxia and photo sequential control was designed. It provides a platform for constructing theranostic pro-prodrugs to release active drugs controlled by hypoxic status and UV illumination.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1359-7345
1364-548X
DOI:10.1039/c6cc02932a